Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : IGC save search
IGC Announces Issuance of Patent for the Treatment of Alzheimer’s Disease Using THC
Published: 2021-07-22 (Crawled : 16:00) - igcinc.us
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 165.54%
H: 18.32%
C: -28.75%
disease alzheimer treatment patent alzheimer’s alzheimer's disease alzheimer's
IGC Receives U.S. Patent for Method and Composition for Treating Seizure Disorders
Published: 2022-06-09 (Crawled : 07:00) - igcinc.us
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 48.37%
H: 14.13%
C: -1.3%
patent
IGC Completes the Final Cohort of its Phase 1 Clinical Trial on Alzheimer’s Patients
Published: 2021-06-24 (Crawled : 01:00) - igcinc.us
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 17.57%
H: 9.2%
C: -5.17%
alzheimer phase 1 trial phase 2 phase 3 alzheimer’s alzheimer's
IGC Acquires Exclusive Rights for a Potential Alzheimer’sDrug Development Candidate
Published: 2022-06-21 (Crawled : 09:00) - igcinc.us
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 9.3%
H: 0.0%
C: 0.0%
potential naphthalene monoimide jncasr
IGC Completes Cohort 1 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients
Published: 2021-05-14 (Crawled : 14:00) - igcinc.us
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 8.0%
H: 3.7%
C: 1.48%
alzheimer phase 1 trial phase 3 phase 2 alzheimer’s alzheimer's
IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s Disease
Published: 2022-12-01 (Crawled : 13:20) - igcinc.us
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 7.49%
H: 3.07%
C: -0.35%
treatment dementia trials drug candidate disease alzheimer’s phase 2
IGC Completes its Phase 1 Clinical Trial on Alzheimer’s Patients, Reports Safety and Tolerability
Published: 2021-09-08 (Crawled : 14:00) - igcinc.us
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 6.92%
H: 1.76%
C: -7.06%
alzheimer phase 1 trial phase 2 phase 3 alzheimer’s alzheimer's
IGC Form 10-Q
Published: 2022-08-07 (Crawled : 20:20) - igcinc.us
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 5.47%
H: 1.72%
C: 0.0%
IGC Reports Financial Results for the Quarter Ended June 30, 2022
Published: 2022-08-08 (Crawled : 17:00) - igcinc.us
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 5.47%
H: 1.72%
C: 0.0%
IGC FORM 10Q Quarter Ended September 30, 2022
Published: 2022-11-01 (Crawled : 23:00) - igcinc.us
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 4.33%
H: 0.0%
C: -10.4%
IGC Reports Financial Results for the Quarter Ended September 30, 2022
Published: 2022-11-01 (Crawled : 23:00) - igcinc.us
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 4.33%
H: 0.0%
C: -10.4%
financial
IGC Form 8-K
Published: 2022-05-12 (Crawled : 22:00) - igcinc.us
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 3.68%
H: 19.44%
C: 7.12%
IGC Reports Financial Results for the Fiscal Year Ended March 31, 2021
Published: 2021-06-15 (Crawled : 13:00) - igcinc.us
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 1.86%
H: 1.22%
C: -3.66%
financial results results
IGC Form 10-K
Published: 2021-06-15 (Crawled : 13:00) - igcinc.us
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 1.86%
H: 1.22%
C: -3.66%
IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022
Published: 2023-02-15 (Crawled : 01:00) - globenewswire.com
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 1.73%
H: 0.0%
C: -2.25%
financial
IGC Applauds Signing of Bipartisan Medical Marijuana and Cannabidiol Research Expansion Act
Published: 2022-12-07 (Crawled : 14:00) - globenewswire.com
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 1.51%
H: 0.0%
C: -2.24%
cannabidiol expansion research medical
IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients
Published: 2021-06-09 (Crawled : 18:00) - igcinc.us
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 0.64%
H: 1.9%
C: -5.7%
alzheimer phase 1 trial phase 3 phase 2 alzheimer’s alzheimer's
Phase 1 Clinical Trial Data Indicate IGC’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients
Published: 2021-12-02 (Crawled : 15:30) - igcinc.us
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 0.0%
H: 23.81%
C: -0.79%
new drug alzheimer dementia drug trial phase 1 phase 2 alzheimer’s alzheimer's
IGC FYE2022 Form 8-K Favorable Preliminary Clinical Trial Results
Published: 2021-12-02 (Crawled : 15:30) - igcinc.us
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
|
| O: 0.0%
H: 23.81%
C: -0.79%
trial trial results results
IGC Form 10-Q
Published: 2022-02-11 (Crawled : 19:00) - igcinc.us
IGC 4 | $0.49 2.92% 0.74% 610K
|
Health Technology
| Email alert
Add to watchlist
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
DEO | News | $140.76 -0.02% 8.27% 560K
|
Consumer Non-Durables
KUKE | $2.88 2.49% 7.64% 360K
|
LYT | $4.22 4.72% 5.62% 1.4M
|
SYY | $76.73 1.44% 5.49% 2.5M
|
Distribution Services
TWI | $11.53 0.96% 4.94% 330K
|
Producer Manufacturing
BTCM | $1.99 -6.13% 4.52% 75K
|
Arts, Entertainment, and Recrea...
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.